FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/31/2025
Back to search
Official data from USPTO
SYRCELT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SYRCELT
ST13
US500000079373376Class
1, 5, 42
Filing
79373376
Registration
7592418
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5, 42
Filing date
04/07/2023
Registration date
12/10/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/10/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
33
Owner location
BE
Examiner
MANCA, ALBERTO I
Law office
L80
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
BePharBel Manufacturing S.A.
Representatives
Bradley M. Stohry Reichel Stohry Dean LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical products for use in the pharmaceutical industrychemical additives and preservatives for use in the manufacture of pharmaceuticals; active chemical ingredients for manufacture of pharmaceutical products for treating cardiovasculardigestiveneurologicalendocrinerespiratoryimmunemuscularurinaryreproductivenutritional and skeletal diseases; chemical additives for use as binding agents in the manufacture of pharmaceuticals for treating cardiovasculardigestiveneurologicalendocrinerespiratoryimmunemuscularurinaryreproductivenutritional and skeletal diseases; chemical carrier excipients for use in the manufacture of pharmaceutical preparations; chemical excipients for the manufacture of pharmaceutical preparations; raw materialcellulose microspheres and microspheres made of cellulosesugarstarch for use in the manufacture of pharmaceuticals; microcrystalline cellulose microspheres for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industryantioxidants and antimicrobials for use in the manufacture of pharmaceuticals; carrier excipients for use in the manufacture of pharmaceutical preparations; excipients for pharmaceutical preparation manufacture
Class 5
Pharmaceutical productssyrupspreparations in the form of granulesliquid pharmaceutical suspensionsfor pharmaceutical purposes for the treatment of cardiovasculardigestiveneurologicalendocrinerespiratoryimmunemuscularurinaryreproductivenutritional and skeletal diseasespharmaceutical preparations for the treatment of cardiovasculardigestiveneurologicalendocrinerespiratoryimmunemuscularurinaryreproductivenutritional and skeletal diseases; medicinessyrupspreparations in the form of granulesliquid pharmaceutical suspensionsfor pharmaceutical purposes for the treatment of cardiovasculardigestiveneurologicalendocrinerespiratoryimmunemuscularurinaryreproductivenutritional and skeletal diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agentsmedicine release agents in the form of gastro-resistant and controlled release microparticles for the controlled release of active ingredients for a wide range of pharmaceutical products; drug delivery agentsmedicine delivery agents in the form of granulated powders for the controlled release of active ingredients for a wide range of pharmaceutical products; syrups for pharmaceutical use for the treatment of cardiovasculardigestiveneurologicalendocrinerespiratoryimmunemuscularurinaryreproductivenutritional and skeletal diseases; syrups being medicines for the treatment of cardiovasculardigestiveneurologicalendocrinerespiratoryimmunemuscularurinaryreproductivenutritional and skeletal diseases; syringes pre-filled with syrups for the treatment of cardiovasculardigestiveneurologicalendocrinerespiratoryimmunemuscularurinaryreproductivenutritional and skeletal diseases; medicines being esomeprazole for oral administration; medicines being omeprazole for oral administration; central nervous system stimulants; hormones for medical use; Pharmaceutical products for the treatment of gastrointestinal disorders; soporifics
Class 42
Pharmaceutical research and development for the pharmaceutical industry; medical and pharmacological research services; research and development services relating to medicines; development of pharmaceutical preparations and medicines; development of pharmaceutical products
Publications
History of USPTO decisions and trademark events.
30 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/11/2025
FIMP
FINAL DISPOSITION PROCESSED
05/11/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/10/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/21/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/10/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/04/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/10/2024
PUBO
PUBLISHED FOR OPPOSITION
09/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/21/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/07/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
08/07/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/07/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
08/07/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/07/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/22/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/22/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/22/2024
RFNT
REFUSAL PROCESSED BY IB
02/14/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/25/2024
RFRR
REFUSAL PROCESSED BY MPU
01/25/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/09/2024
CNRT
NON-FINAL ACTION WRITTEN
01/08/2024
DOCK
ASSIGNED TO EXAMINER
01/04/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/08/2023
MAFR
APPLICATION FILING RECEIPT MAILED
07/11/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/07/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/06/2023
Continuous trademark protection
Get notified about every new filing that threatens SYRCELT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.